How I treat mixed-phenotype acute leukemia

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Mixed-phenotype acute leukemia (MPAL) is a rare and heterogeneous myeloid or lymphoid malignancy.
• Historically, MPAL has been described using various terms and classification systems.
• Current MPAL classification relies on limited lineage-specific markers from the 2008 WHO monograph.

Observation:

• MPAL in adults often presents with therapeutic resistance, frequently linked to adverse cytogenetic abnormalities.
• There is a lack of prospective, controlled clinical trials to establish definitive treatment guidelines for MPAL.
• Limited data suggest an acute lymphoblastic leukemia-like regimen followed by allogeneic stem-cell transplant may be beneficial.

Findings:

• The addition of tyrosine kinase inhibitors is recommended for MPAL patients with the t(9;22) translocation.
• The optimal role of immunophenotypic and genetic markers in guiding MPAL chemotherapy and postremission strategies remains unclear.
• The efficacy of targeted therapies in non-Ph-positive MPAL requires further investigation.

Implications:

• Improved understanding of MPAL biology and treatment is crucial for this rare leukemia.
• Further research is needed to develop targeted therapies and optimize treatment strategies for MPAL.
• Establishing clear diagnostic and therapeutic guidelines will enhance outcomes for MPAL patients.